Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill may keep yeast infections away for good

NCT ID NCT03562156

Disease control Sponsor: Mycovia Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new oral medication, oteseconazole, to see if it can prevent recurrent yeast infections in women who have had at least three infections in the past year. Participants first received standard treatment for their current infection, then took either oteseconazole or a placebo for 12 weeks, followed by 36 weeks of monitoring. The goal was to see if the drug could reduce the number of future infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

438 people

The number who actually took part.

Started

Aug 2018

Finished

Aug 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * 3 or more episodes of acute VVC in the past 12 months * Positive KOH or Gram stain * Total vulvovaginal signs and symptoms score of ≥3 at screening visit * Total vulvovaginal signs and symptoms score of \<3 at baseline visit * Must be able to swallow pills Key Exclusion Criteria: * Presence or a history of another vaginal or vulvar condition(s) * Evidence of major organ system disease * History of cervical cancer * Poorly controlled diabetes mellitus * Pregnant * Recent use of topical or systemic antifungal or antibacterial drugs * Recent use of immunosuppressive or systemic corticosteroid therapies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent vulvovaginal candidiasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vulvovaginal candidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent vulvovaginal candidiasis

Contacts and locations

Locations

  • 31102

    Houston, Texas, 77054, United States

  • 31103

    Las Vegas, Nevada, 89128, United States

  • 31105

    Metairie, Louisiana, 70006, United States

  • 31106

    Wellington, Florida, 33414, United States

  • 31107

    Metarie, Louisiana, 70001, United States

  • 31108

    San Diego, California, 92111, United States

  • 31111

    Norcross, Georgia, 30095, United States

  • 31113

    Richmond, Virginia, 23225, United States

  • 31114

    Lawrenceville, New Jersey, 08648, United States

  • 31116

    Morehead City, North Carolina, 28557, United States

  • 31117

    Draper, Utah, 84020, United States

  • 31118

    Las Vegas, Nevada, 89123, United States

  • 31120

    Bristol, Tennessee, 37620, United States

  • 31123

    Birmingham, Alabama, 35233, United States

  • 31125

    Franklin, Ohio, 45005, United States

  • 31127

    West Seneca, New York, 14224, United States

  • 31132

    Greensboro, North Carolina, 27408, United States

  • 31134

    Philadelphia, Pennsylvania, 19102, United States

  • 31139

    Lauderdale Lakes, Florida, 33319, United States

  • 31142

    Port Jefferson, New York, 11777, United States

  • 31143

    Sarasota, Florida, 34239, United States

  • 31144

    Raleigh, North Carolina, 27607, United States

  • 31145

    Winston-Salem, North Carolina, 27103, United States

  • 31146

    Covington, Louisiana, 70433, United States

  • 31147

    Fall River, Massachusetts, 02720, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.